Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2017 |
| gptkbp:ATCCode |
L01XC31
|
| gptkbp:CASNumber |
1537032-82-8
|
| gptkbp:developedBy |
gptkb:Pfizer
gptkb:Merck_KGaA |
| gptkbp:form |
solution for infusion
|
| gptkbp:genericName |
gptkb:avelumab
|
| https://www.w3.org/2000/01/rdf-schema#label |
Bavencio
|
| gptkbp:indication |
gptkb:urothelial_carcinoma
gptkb:advanced_renal_cell_carcinoma metastatic Merkel cell carcinoma |
| gptkbp:KEGGID |
D10813
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
gptkb:monoclonal_antibody
|
| gptkbp:mechanismOfAction |
PD-L1 inhibitor
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:PubChem_CID |
gptkb:DB12010
gptkb:CHEMBL3989989 |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue rash elevated liver enzymes infusion-related reaction |
| gptkbp:target |
PD-L1
|
| gptkbp:UNII |
8N3DW7272P
|
| gptkbp:bfsParent |
gptkb:默克
|
| gptkbp:bfsLayer |
5
|